Molecular Devices
Molecular Devices, LLC, located in San Jose, California, specializes in bioanalytical solutions for protein and cell biology, primarily serving life science research, pharmaceutical, and biotherapeutic development sectors. The company offers a comprehensive range of products, including microplate readers, cellular imaging systems, high-throughput screening platforms, and acquisition and analysis software. Their portfolio also features biosensors, kits, and advanced data analysis software designed to enhance research workflows and ensure data integrity. Molecular Devices enables scientists to conduct critical applications such as cell counting, protein detection, and stem cell research, ultimately accelerating the discovery of new therapeutics. With over 130,000 installations globally, the company has contributed to significant scientific advancements, evidenced by more than 25,000 peer-reviewed publications. As a subsidiary of Danaher Corporation, Molecular Devices employs nearly 1,000 skilled professionals and maintains a strong presence in the field of bioanalytical measurement solutions.
Top Stages
2 past transactions
Cellesce
Acquisition in 2022
Cellesce Ltd is a biochemical engineering company located in Cardiff, UK, specializing in cell expansion focused on organoids. The company provides bioprocessing technology and engineering services aimed at drug discovery and organ-on-a-chip applications. Cellesce is known for its expertise in the development, scale-up, and manufacture of patient-derived organoids, utilizing proprietary bioprocesses and bioreactors. These technologies allow for the expansion of both normal and cancer patient-derived organoids for various applications, including drug screening. Cellesce employs in-line sensors and real-time monitoring to ensure precise culture conditions, enhance yield, control organoid size, and minimize variability across different batches and users, ultimately supporting healthcare professionals in drug efficacy testing.
LJL Biosystems
Acquisition in 2000
LJL is developing and marketing proprietary technologies and products to accelerate and enhance the drug discovery process. LJL's proprietary integrated technology platform is comprised of instrumentation and fluorescence-based and other assay technologies designed to provide a flexible solution to the current and evolving HTS requirements of drug discovery laboratories. The drug discovery process involves several stages including target identification, compound synthesis, assay development, screening and lead optimization.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.